Regulation of non-histone protein functions by histone deacetylases
Regulation of non-histone protein functions by histone deacetylases
批准号:
7851182
负责人:
EDWARD SETO
金额:
$34.24万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-01 至 2012-05-31
关键词:
AcetylationAcute Lymphocytic LeukemiaAddressAffectAmino AcidsApoptosisAtaxia TelangiectasiaBindingBiochemicalBiologicalBiological ProcessBrainCell Cycle ProgressionCell NucleusCell ProliferationCell SurvivalCell physiologyCellsChildhoodChromatinChromatin ModelingChromosome SegregationChromosomesCloningComplementComplement Factor DComplexCoupledCytoplasmCytoplasmic ProteinDNADNA biosynthesisDataDeacetylationDefectDiagnosticDiseaseEnzymesEventExcisionFibroblastsGene ExpressionGene TargetingGenesGenetic RecombinationGenetic TranscriptionGoalsHDAC2 geneHandHistone AcetylationHistone DeacetylaseHistone DeacetylationHistonesHumanIonizing radiationLaboratoriesLymphomaLysineMalignant NeoplasmsMediatingModificationMolecularMusMutateNerve DegenerationPathway interactionsPatientsPlayPost-Translational Protein ProcessingProtein SubunitsProteinsRadiation ToleranceRegulationRoleSiteSmall Interfering RNASubstrate SpecificityTP53 geneTailTestingTherapeuticYangabstractingamino groupbasebody systemhistone deacetylase 3histone modificationinsightinterestnovelpreventprotein complexprotein functionresponsetranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Histone deacetylases (HDACs) are enzymes that regulate the functions of histone proteins by catalyzing the removal of acetyl groups from lysine residues. They play a pivotal role in the regulation of gene transcription and are indispensable in numerous eukaryotic biological processes involving chromatin. Results from many studies suggest that HDACs control cell cycle progression, cell proliferation, and differentiation. Remarkably, recent studies reveal that many
“histone” deacetylases possess the ability to deacetylate not only histones but also non-histone protein substrates. Ataxia telangiectasia (AT) is a rare, autosomal recessive, progressive, neurodegenerative childhood disease that affects the brain and multiple other body systems. About 20% of AT patients develop cancer, most frequently acute lymphocytic leukemia or lymphoma. The ataxiatelangiectasia group D complementing (ATDC) gene was originally isolated on the basis of its ability to complement the ionizing radiation sensitivity defect of AT group D fibroblasts. Later analysis revealed that ATDC does not affect radioresistant DNA synthesis and is most likely not mutated in any AT patients. Therefore, although the ATDC gene product acts indirectly to suppress radiosensitivity in AT cells, the mechanism by which ATDC complements
radiosensitivity in AT cells and how ATDC activities and functions are regulated are entirely unknown.
Preliminary results indicate that ATDC is an acetylated protein, and its acetylation status is closely controlled by HDAC9. This revised proposal, in response to the ARRA, will test the overall hypothesis that HDAC9 is critically involved in regulating the activities and functions of a non-histone protein, ATDC. The long-term goal of this project is to explore novel biological roles of HDAC9 and to obtain a complete understanding of how HDAC9 regulates important
cellular processes by targeting non-histone proteins. Immediate emphasis will be placed on clarifying the potential involvement of HDAC9 in the deacetylation of the ATDC protein that consequently influences a pathway that could affect radiosensitivity in AT cells. Understanding the function and regulation of ATDC, and its mechanism of suppression of radiosensitivity in AT cells, will provide important insights into alternative pathways involved in the cellular response to ionizing radiation. Additionally, abnormal HDACs are strongly correlated with many human maladies, such as cancer. Therefore, a thorough understanding of
the role of HDAC9 in the modification of ATDC will provide not only tremendous insight into the novel functions and mechanisms of action of HDACs but also potential diagnostic and therapeutic approaches for the treatment of diseases.
Description of changes:
The objectives and hypotheses of this revised proposal remain unchanged. As a result, there are minimal changes in this revised abstract section.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.2741/s303
发表时间:
2012-01-01
期刊:
Frontiers in bioscience (Scholar edition)
影响因子:
--
作者:
[Telles E, Seto E]
通讯作者:
Seto E
Targeting lysine acetyltransferase MOF/KAT8 in lung cancer
-
批准号:10601761
-
项目类别:
-
资助金额:$39.52万
-
财政年份:2023
-
负责人:EDWARD SETO
-
依托单位:
Targeting SIRT1 in Mantle Cell Lymphoma
-
批准号:9480931
-
项目类别:
-
资助金额:$9.48万
-
财政年份:2014
-
负责人:EDWARD SETO
-
依托单位:
Targeting SIRT1 in Mantle Cell Lymphoma
-
批准号:8748681
-
项目类别:
-
资助金额:$34.96万
-
财政年份:2014
-
负责人:EDWARD SETO
-
依托单位:
Targeting SIRT1 in Mantle Cell Lymphoma
-
批准号:9068864
-
项目类别:
-
资助金额:$21.31万
-
财政年份:2014
-
负责人:EDWARD SETO
-
依托单位:
The Basic and Translational Implication of SIRT1 and DNMT1 in Cancer
-
批准号:8507658
-
项目类别:
-
资助金额:$32.87万
-
财政年份:2012
-
负责人:EDWARD SETO
-
依托单位:
The Basic and Translational Implication of SIRT1 and DNMT1 in Cancer
-
批准号:8658413
-
项目类别:
-
资助金额:$33.91万
-
财政年份:2012
-
负责人:EDWARD SETO
-
依托单位:
The Basic and Translational Implication of SIRT1 and DNMT1 in Cancer
-
批准号:8345095
-
项目类别:
-
资助金额:$34.96万
-
财政年份:2012
-
负责人:EDWARD SETO
-
依托单位:
The Basic and Translational Implication of SIRT1 and DNMT1 in Cancer
-
批准号:8842463
-
项目类别:
-
资助金额:$13.66万
-
财政年份:2012
-
负责人:EDWARD SETO
-
依托单位:
Regulation and Functions of Human Histone Deacetylase 8
-
批准号:6814106
-
项目类别:
-
资助金额:$30.07万
-
财政年份:2004
-
负责人:EDWARD SETO
-
依托单位:
Regulation and Functions of Human Histone Deacetylase 8
-
批准号:6902665
-
项目类别:
-
资助金额:$30.07万
-
财政年份:2004
-
负责人:EDWARD SETO
-
依托单位:
Regulation and Functions of Human Histone Deacetylase 8
-
批准号:7048570
-
项目类别:
-
资助金额:$29.37万
-
财政年份:2004
-
负责人:EDWARD SETO
-
依托单位:
Regulation and Functions of Human Histone Deacetylase 8
-
批准号:7395033
-
项目类别:
-
资助金额:$29.04万
-
财政年份:2004
-
负责人:EDWARD SETO
-
依托单位:
Regulation and Functions of Human Histone Deacetylase 8
-
批准号:7224869
-
项目类别:
-
资助金额:$28.52万
-
财政年份:2004
-
负责人:EDWARD SETO
-
依托单位:
Molecular Targets For Cancer Therapy
-
批准号:6777013
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2002
-
负责人:EDWARD SETO
-
依托单位:
Mechanisms of Transcription Factor Yin Yang 1
-
批准号:6896517
-
项目类别:
-
资助金额:$24.8万
-
财政年份:2002
-
负责人:EDWARD SETO
-
依托单位:
Mechanisms of Transcription Factor Yin Yang 1
-
批准号:6637890
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2002
-
负责人:EDWARD SETO
-
依托单位:
Mechanisms of Transcription Factor Yin Yang 1
-
批准号:6535782
-
项目类别:
-
资助金额:$27.41万
-
财政年份:2002
-
负责人:EDWARD SETO
-
依托单位:
Mechanisms of Transcription Factor Yin Yang 1
-
批准号:6754382
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2002
-
负责人:EDWARD SETO
-
依托单位:
Molecular Targets For Cancer Therapy
-
批准号:6591100
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2002
-
负责人:EDWARD SETO
-
依托单位:
Molecular Targets For Cancer Therapy
-
批准号:6647682
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2002
-
负责人:EDWARD SETO
-
依托单位:
海外基金